Rodriguez, Caitlin M.
Wright, Shannon E.
Kearse, Michael G.
Haenfler, Jill M.
Flores, Brittany N.
Liu, Yu
Ifrim, Marius F.
Glineburg, Mary R.
Krans, Amy
Jafar-Nejad, Paymaan
Sutton, Michael A.
Bassell, Gary J. http://orcid.org/0000-0003-2622-0127
Parent, Jack M. http://orcid.org/0000-0002-2972-1528
Rigo, Frank
Barmada, Sami J. http://orcid.org/0000-0002-9604-968X
Todd, Peter K. http://orcid.org/0000-0003-4781-6376
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (F31 NS090883, T32-NS076401, F32NS089124, T32NS007222, R01NS097542, P30AG053760, P30NS05507708, T32NS007222, P30NS05507708, P30AG053760, R01NS097542, R01NS099280, R01NS086810)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (K99GM126064)
FRAXA Research Foundation
Ionis Pharmaceuticals
Article History
Received: 8 October 2018
Accepted: 10 January 2020
First Online: 17 February 2020
Competing interests
: P.K.T. served as a consultant with Denali Therapeutics and has licensed technology through the University of Michigan to Denali. P.K.T., C.M.R., F.R. and P.J. hold a patent on ASOs targeting CGG RAN. F.R. and P.J. are paid employees of Ionis Pharmaceuticals. All other authors declare no competing interests.